First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Completed

Looking for future studies?

Key information

Conditions

Colonic Neoplasms Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases Rectal Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with metastatic cancer of colon or rectum

Treatment and study plan

First-Line Bevacizumab and Chemotherapy

Radiation

Chemotherapy

Bevacizumab

Drug

Chemotherapy

Primary outcomes

Effectiveness

Time frame: overall

Secondary outcomes

Quality of life

Time frame: overall

Sponsors and collaborators

Lead sponsor

King Faisal Specialist Hospital & Research Center

Other

Registry information

Important dates

Study start: 2007
Primary completion: 2013
Study completion: 2013
First posted: Oct 2, 2007
Registry last updated: Dec 17, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed